-5%
Active substance: Posaconazole, a triazole antifungal.
Mechanism: Blocks ergosterol synthesis by inhibiting lanosterol 14-α-demethylase (CYP450 enzyme).
Effect: Leads to ergosterol depletion and accumulation of toxic sterol precursors, weakening fungal cell membranes → cell death.
Osapiderm is indicated for patients aged 13 years and above in the treatment of:
- Invasive Aspergillosis – in patients refractory or intolerant to Amphotericin B or Itraconazole.
- Fusariosis – in patients refractory or intolerant to Amphotericin B.
- Chromoblastomycosis and Mycetoma – in patients refractory or intolerant to Itraconazole.
- Coccidioidomycosis – in patients refractory or intolerant to Amphotericin B, Itraconazole, or Fluconazole, or who cannot tolerate these drugs.
- Also indicated for prophylaxis of invasive fungal infections in:
- Patients receiving remission-induction chemotherapy for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS) with expected prolonged neutropenia.
- Hematopoietic Stem Cell Transplant (HSCT) recipients undergoing high-dose immunosuppressive therapy for graft-versus-host disease.
👉 Refractoriness is defined as infection progression or no improvement after ≥7 days of effective antifungal therapy.
👉 Use only under the supervision of a registered physician.